2. JAK/STAT Signaling Protein Tyrosine Kinase/RTK Autophagy
  3. EGFR Autophagy
  4. Erlotinib

Erlotinib  (Synonyms: 埃罗替尼; CP-358774; NSC 718781; OSI-774)

目录号: HY-50896 纯度: 99.96%
COA 产品使用指南

摩尔计算器

Erlotinib (CP-358774) 是一种直接作用的 EGFR 酪氨酸激酶抑制剂，对人 EGFR 的 IC50 为 2 nM。Erlotinib 可降低完整肿瘤细胞的 EGFR 自磷酸化，IC50 为 20 nM。Erlotinib 用于非小细胞肺癌的研究。Erlotinib 是一种点击化学试剂。它含有 Alkyne 基团，可以和含有 Azide 基团的分子发生铜催化的叠氮-炔环加成反应 (CuAAc)。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Erlotinib Chemical Structure

Erlotinib Chemical Structure

CAS No. : 183321-74-6

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥550
In-stock
100 mg ￥500
In-stock
500 mg ￥800
In-stock
1 g ￥1360
In-stock
5 g   询价  
10 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Erlotinib:

Erlotinib 相关抗体

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 96 篇科研文献

WB
IF

    Erlotinib purchased from MCE. Usage Cited in: Cancer Med. 2019 Dec;8(18):7793-7808.  [Abstract]

    Western blots of proteins expression in EGFR signaling pathways in LN229 and U87 cells with MYST1/GFP overexpression after erlotinib (200 ng/mL)/DMSO treatment.

    Erlotinib purchased from MCE. Usage Cited in: Mol Oncol. 2018 Mar;12(3):305-321.  [Abstract]

    Western blot analysis of total and phosphorylated EGFR expression in two breast cancer cells pretreated with different concentration Erlotinib for 4h.

    Erlotinib purchased from MCE. Usage Cited in: Anal Chim Acta. 2018 Nov 22;1032:138-146.  [Abstract]

    30 min after EGF(100 ng/mL) and EGFP-sSH2(Arg)9 (5 μM) are added into the MDA-MB-468 cell culture medium, Erlotinib is added into the cell culture medium (100 nM), and the picture was collected at 30 min after Erlotinib treatment.

    Erlotinib purchased from MCE. Usage Cited in: Front Pharmacol. 2018 Jun 21;9:660.  [Abstract]

    By Western blotting, the α-SMA and palladin proteins are determined in cells that are pretreated with NF-κB (JSH-23), Wnt/β-catenin (XAV939), EGFR (erlotinib), p38 MAPK (TAK-715), and Smad3 (SIS3) inhibitors and are followed by TWEAK stimulation.

    Erlotinib purchased from MCE. Usage Cited in: Oncogene. 2017 May 11;36(19):2643-2654.  [Abstract]

    Effects of anti-cancer agents Oxaliplatin (25 mM), Erlotinib (25 mM) and cAMP inducer Forskolin (25 mM) on FOXO3 expression in Panc-1 cells are assessed for 72h (n=3).

    查看 EGFR 亚型特异性产品:

    查看所有亚型
    EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1]. Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

    IC50 & Target[1]

    EGFR

    2 nM (IC50, Cell Free Assay)

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    16HBE14o- CC50
    1.32 μM
    Compound: Erlotinib
    Cytotoxicity against human 16HBE14o- cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human 16HBE14o- cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 36509365]
    A-375 IC50
    17.86 μM
    Compound: Erlotinib
    Cytotoxicity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35685617]
    A-375 IC50
    25.85 μM
    Compound: Erlotinib
    Antiproliferative activity against human A-375 cells incubated for 24 hrs by MTT assay
    Antiproliferative activity against human A-375 cells incubated for 24 hrs by MTT assay
    		[PMID: 36513215]
    A-375 IC50
    27.26 μM
    Compound: Erlotinib
    Antiproliferative activity aganist human A375 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity aganist human A375 cells incubated for 72 hrs by MTT assay
    		[PMID: 31493743]
    A-375 IC50
    5.12 μM
    Compound: 1
    Antiproliferative activity against human A375 cells after 48 hrs by propidium iodide fluorescence assay
    Antiproliferative activity against human A375 cells after 48 hrs by propidium iodide fluorescence assay
    		[PMID: 30744932]
    A-431 IC50
    > 10000 nM
    Compound: Erlotinib
    Inhibition of IGF1R intracellular phosphorylation in human A431 cells by ELISA
    Inhibition of IGF1R intracellular phosphorylation in human A431 cells by ELISA
    		[PMID: 20346655]
    A-431 IC50
    0.409 μM
    Compound: 2
    Antiproliferative activity against human A431 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A431 cells after 72 hrs by SRB assay
    		[PMID: 24183742]
    A-431 GI50
    0.47 μM
    Compound: Tarceva
    Growth inhibition of human A431 cells overexpressing EGFR after 72 hrs by MTT assay
    Growth inhibition of human A431 cells overexpressing EGFR after 72 hrs by MTT assay
    		[PMID: 17983745]
    A-431 IC50
    0.56 μM
    Compound: 2
    Antiproliferative activity against human A431 cells assessed as growth inhibition after 72 hrs by SRB assay
    Antiproliferative activity against human A431 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 24565969]
    A-431 IC50
    0.75 μM
    Compound: Erlotinib
    Antiproliferative activity against human A431 cells overexpressing EGFR assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human A431 cells overexpressing EGFR assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 32139324]
    A-431 IC50
    0.75 μM
    Compound: Tarceva
    Cytotoxicity against human A431 cells overexpressing EGFR assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A431 cells overexpressing EGFR assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 27524310]
    A-431 IC50
    0.75 μM
    Compound: Erlotinib, Tarceva
    Cytotoxicity against human A431 cells expressing EGFR after 72 hrs by MTT assay
    Cytotoxicity against human A431 cells expressing EGFR after 72 hrs by MTT assay
    		[PMID: 24411123]
    A-431 IC50
    0.844 μM
    Compound: Erlotinib
    Antiproliferative activity against human A431 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human A431 cells after 72 hrs by CCK-8 assay
    		[PMID: 26487917]
    A-431 GI50
    0.915 μM
    Compound: Tar
    Growth inhibition of human A431 cells after 72 hrs by MTT assay
    Growth inhibition of human A431 cells after 72 hrs by MTT assay
    		[PMID: 19969465]
    A-431 IC50
    1.2 nM
    Compound: Erlotinib
    Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method
    Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method
    		[PMID: 25882519]
    A-431 IC50
    1.2 nM
    Compound: Erlotinib
    Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay
    Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay
    		[PMID: 24890652]
    A-431 IC50
    1.2 μM
    Compound: 1
    Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA
    Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA
    		[PMID: 22204741]
    A-431 IC50
    1.2 μM
    Compound: Erlotinib
    Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA
    Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA
    		[PMID: 23434139]
    A-431 IC50
    1.2 μM
    Compound: Erlotinib
    Inhibition of EGFR in human A431 cells pretreated for 60 mins measured after 1 hr by ELISA
    Inhibition of EGFR in human A431 cells pretreated for 60 mins measured after 1 hr by ELISA
    		[PMID: 22739090]
    A-431 IC50
    1.2 μM
    Compound: 1
    Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA
    Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA
    		[PMID: 20403700]
    A-431 IC50
    1.2 μM
    Compound: 2
    Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis
    Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis
    		[PMID: 23375090]
    A-431 IC50
    1.41 μM
    Compound: Erlotinib
    Cytotoxicity against human A-431 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A-431 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 32320239]
    A-431 IC50
    1.87 μg/mL
    Compound: Erlotinib
    Antiproliferative activity against human A431 cells after 24 to 48 hrs by WST1 assay
    Antiproliferative activity against human A431 cells after 24 to 48 hrs by WST1 assay
    		[PMID: 22901387]
    A-431 IC50
    11.85 μM
    Compound: Erlotinib
    Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33640672]
    A-431 IC50
    2.2 μM
    Compound: 2
    Antiproliferative activity against human A-431 cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay
    Antiproliferative activity against human A-431 cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay
    		[PMID: 31869655]
    A-431 IC50
    2.5 μM
    Compound: 6
    Cytotoxicity against human A431 cells by Alamar Blue assay
    Cytotoxicity against human A431 cells by Alamar Blue assay
    		10.1039/C2MD00317A
    A-431 IC50
    28.7 μM
    Compound: Erlotinib
    Cytotoxicity against human A-431 cells expressing EGFR assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human A-431 cells expressing EGFR assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34046625]
    A-431 EC50
    2805 nM
    Compound: 16
    Cytotoxicity against human A-431 cells expressing wild type EGFR assessed as reduction in cell viability incubated for 96 hrs by CellTiter-Glo assay
    Cytotoxicity against human A-431 cells expressing wild type EGFR assessed as reduction in cell viability incubated for 96 hrs by CellTiter-Glo assay
    		[PMID: 37197473]
    A-431 IC50
    31.94 μM
    Compound: Erlotinib
    Antiproliferative activity against human A-431 cells overexpressing EGFR assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human A-431 cells overexpressing EGFR assessed as cell growth inhibition by MTT assay
    		[PMID: 34995690]
    A-431 IC50
    34 nM
    Compound: Erlotinib
    Inhibition of EGFR intracellular phosphorylation in human A431 cells by ELISA
    Inhibition of EGFR intracellular phosphorylation in human A431 cells by ELISA
    		[PMID: 20346655]
    A-431 IC50
    5.14 μM
    Compound: Erlotinib
    Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31078412]
    A-431 IC50
    55 nM
    Compound: Erlotinib
    Cytotoxicity against human A431 cells over expressing EGFR after 48 hrs by MTT assay
    Cytotoxicity against human A431 cells over expressing EGFR after 48 hrs by MTT assay
    		[PMID: 22414612]
    A-431 IC50
    96 nM
    Compound: 2
    Cytotoxicity against human A431 cells after 72 hrs by SRB assay
    Cytotoxicity against human A431 cells after 72 hrs by SRB assay
    		[PMID: 19888761]
    A498 IC50
    12500 nM
    Compound: Erlotinib
    Antiproliferative activity against human A498 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A498 cells after 48 hrs by MTT assay
    		[PMID: 29057042]
    A498 IC50
    25.6 μM
    Compound: 2
    Antiproliferative activity against human A498 cells expressing EGFR and Src after 48 hrs by SRB assay
    Antiproliferative activity against human A498 cells expressing EGFR and Src after 48 hrs by SRB assay
    		[PMID: 26188620]
    A549 IC50
    > 100 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell Titer Glo luminescent cell viability assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell Titer Glo luminescent cell viability assay
    		[PMID: 27614407]
    A549 EC50
    > 1000 nM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    A549 IC50
    > 50 μM
    Compound: 6
    Cytotoxicity against human A549 cells by Alamar Blue assay
    Cytotoxicity against human A549 cells by Alamar Blue assay
    		10.1039/C2MD00317A
    A549 IC50
    > 50 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
    		[PMID: 32739648]
    A549 IC50
    0.008 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells harboring wild type EGFR assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells harboring wild type EGFR assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 32402937]
    A549 IC50
    0.02 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay
    		[PMID: 27010345]
    A549 GI50
    0.03 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 23391364]
    A549 IC50
    0.03 μM
    Compound: ERL
    Cytotoxicity against human A549 Cells by MTT assay
    Cytotoxicity against human A549 Cells by MTT assay
    		[PMID: 31129455]
    A549 IC50
    0.04 μM
    Compound: Erlotinib
    Antiproliferative activity human A549 cells after 48 hrs by propidium iodide staining-based fluorescence assay
    Antiproliferative activity human A549 cells after 48 hrs by propidium iodide staining-based fluorescence assay
    		[PMID: 29407956]
    A549 IC50
    0.064 μM
    Compound: Erlotinib
    Inhibition of human HER2 in human A549 cells by ELISA method
    Inhibition of human HER2 in human A549 cells by ELISA method
    		[PMID: 30826508]
    A549 IC50
    0.1 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 25172421]
    A549 IC50
    0.13 μg/mL
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 21920766]
    A549 IC50
    0.13 μg/mL
    Compound: Erlotinib, ZD-1839
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 21763148]
    A549 IC50
    0.13 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 24630412]
    A549 IC50
    0.13 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 24607998]
    A549 IC50
    0.13 μM
    Compound: Erlotinib
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 24144854]
    A549 IC50
    0.13 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 23962660]
    A549 IC50
    0.22 μM
    Compound: Erlotinib
    Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
    		[PMID: 32739648]
    A549 IC50
    0.27 μM
    Compound: Erlotinib, ZD-1839
    Antiproliferative activity against human A549 cells expressing EGFR assessed as inhibition of basal cell growth after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells expressing EGFR assessed as inhibition of basal cell growth after 48 hrs by MTT assay
    		[PMID: 21763148]
    A549 EC50
    0.29 μM
    Compound: Erlotinib
    Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
    		[PMID: 35569690]
    A549 IC50
    0.73 μM
    Compound: Erlotinib
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 29028534]
    A549 IC50
    1.04 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33479688]
    A549 IC50
    1.23 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37122544]
    A549 IC50
    10 μM
    Compound: Erlotinib
    Cytotoxicity against human A549 cells incubated for 2 to 4 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 2 to 4 hrs by MTT assay
    		[PMID: 33771586]
    A549 IC50
    10.26 μM
    Compound: Erlotinib
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 30562699]
    A549 IC50
    10.39 μM
    Compound: 1; Erlo
    Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 30108891]
    A549 IC50
    11 nM
    Compound: 3
    Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA
    Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA
    		[PMID: 26756222]
    A549 IC50
    11.68 μM
    Compound: Erlotinib
    Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay based microtiter plate analysis
    Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay based microtiter plate analysis
    		[PMID: 34438126]
    A549 IC50
    11.8 μM
    Compound: Erlotinib
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 32320239]
    A549 IC50
    16.43 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33640672]
    A549 IC50
    17.32 μM
    Compound: Erlotinib
    Anticancer activity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 29549841]
    A549 IC50
    17.86 μM
    Compound: Erlotinib
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35685617]
    A549 IC50
    2.63 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth by MTT assay
    		[PMID: 32949719]
    A549 IC50
    2.98 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 32739648]
    A549 IC50
    20 μM
    Compound: Erlotinib
    Antiproliferative activity against wild type human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against wild type human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31446247]
    A549 IC50
    20.86 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 33423463]
    A549 IC50
    21.3 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 28886509]
    A549 IC50
    22.35 μM
    Compound: Erlotinib
    Antiproliferative activity aganist human A549 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity aganist human A549 cells incubated for 72 hrs by MTT assay
    		[PMID: 31493743]
    A549 IC50
    27.55 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31078412]
    A549 IC50
    3.8 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
    		[PMID: 31671308]
    A549 IC50
    30 nM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 37122549]
    A549 IC50
    33.03 μM
    Compound: Erlotinib
    Cytotoxicity against human A549 cells after 4 to 5 days by MTT assay
    Cytotoxicity against human A549 cells after 4 to 5 days by MTT assay
    		[PMID: 20466555]
    A549 IC50
    34.16 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay
    		[PMID: 36513215]
    A549 IC50
    4.28 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 30503938]
    A549 IC50
    47.74 μM
    Compound: Erlotinib
    Cytotoxicity against human A549 cells expressing EGFR assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells expressing EGFR assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 34046625]
    A549 IC50
    6.26 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells assessed as viable cells after 48 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as viable cells after 48 hrs by CCK8 assay
    		[PMID: 26879314]
    A549 IC50
    7.099 μM
    Compound: Erlotinib
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 24900830]
    A549 IC50
    7.35 μM
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by cck8 assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by cck8 assay
    		[PMID: 27234887]
    A549 IC50
    7.59 μM
    Compound: 4
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay
    		[PMID: 25468044]
    A549 IC50
    9.1 μM
    Compound: 4
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay
    		[PMID: 25468044]
    A549 IC50
    9.48 μg/mL
    Compound: Erlotinib
    Antiproliferative activity against human A549 cells after 24 to 48 hrs by WST1 assay
    Antiproliferative activity against human A549 cells after 24 to 48 hrs by WST1 assay
    		[PMID: 22901387]
    AU565 IC50
    3.3 μM
    Compound: Erlotinib
    Antiproliferative activity against human AU565 cells incubated for 72 hrs by ATPlite luminescence assay
    Antiproliferative activity against human AU565 cells incubated for 72 hrs by ATPlite luminescence assay
    		[PMID: 27614407]
    B16-F10 IC50
    0.02 μg/mL
    Compound: Erlotinib, ZD-1839
    Antiproliferative activity against mouse B16F10 cells assessed as inhibition of serum-stimulated cell growth after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16F10 cells assessed as inhibition of serum-stimulated cell growth after 48 hrs by MTT assay
    		[PMID: 21763148]
    B16-F10 IC50
    0.022 μg/mL
    Compound: Erlotinib
    Antiproliferative activity against mouse B16-F10 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16-F10 cells after 48 hrs by MTT assay
    		[PMID: 21920766]
    B16-F10 IC50
    0.05 μM
    Compound: Erlotinib
    Antiproliferative activity against mouse B16/F10 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16/F10 cells after 48 hrs by MTT assay
    		[PMID: 23245802]
    B16-F10 IC50
    0.1 μM
    Compound: Tarceva
    Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay
    		[PMID: 22361272]
    B16-F10 IC50
    0.12 μM
    Compound: Erlotinib
    Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay
    		[PMID: 28988624]
    B16-F10 IC50
    0.17 μM
    Compound: Erlotinib
    Antiproliferative activity against mouse B16F10 cells after 12 hrs by MTT assay
    Antiproliferative activity against mouse B16F10 cells after 12 hrs by MTT assay
    		[PMID: 26652482]
    B16-F10 IC50
    0.94 μg/mL
    Compound: Erlotinib
    Antiproliferative activity against mouse B16F10 cells after 24 to 48 hrs by WST1 assay
    Antiproliferative activity against mouse B16F10 cells after 24 to 48 hrs by WST1 assay
    		[PMID: 22901387]
    BaF3 GI50
    < 0.5 μM
    Compound: Erlotinib
    Growth inhibition of mouse BA/F3 cells expressing EGFR Del1 mutant after 96 hrs by cell titer-glo assay
    Growth inhibition of mouse BA/F3 cells expressing EGFR Del1 mutant after 96 hrs by cell titer-glo assay
    		[PMID: 20222733]
    BaF3 GI50
    < 0.5 μM
    Compound: Erlotinib
    Growth inhibition of mouse BA/F3 cells expressing EGFR Del3 mutant after 96 hrs by cell titer-glo assay
    Growth inhibition of mouse BA/F3 cells expressing EGFR Del3 mutant after 96 hrs by cell titer-glo assay
    		[PMID: 20222733]
    BaF3 GI50
    < 0.5 μM
    Compound: Erlotinib
    Growth inhibition of mouse BA/F3 cells expressing EGFR Del5 mutant after 96 hrs by cell titer-glo assay
    Growth inhibition of mouse BA/F3 cells expressing EGFR Del5 mutant after 96 hrs by cell titer-glo assay
    		[PMID: 20222733]
    BaF3 GI50
    < 0.5 μM
    Compound: Erlotinib
    Growth inhibition of mouse BA/F3 cells expressing EGFR L858R mutant after 96 hrs by cell titer-glo assay
    Growth inhibition of mouse BA/F3 cells expressing EGFR L858R mutant after 96 hrs by cell titer-glo assay
    		[PMID: 20222733]
    BaF3 GI50
    > 5 μM
    Compound: Erlotinib
    Growth inhibition of mouse BA/F3 cells expressing EGFR Del1 and Thr790Met mutant after 96 hrs by cell titer-glo assay
    Growth inhibition of mouse BA/F3 cells expressing EGFR Del1 and Thr790Met mutant after 96 hrs by cell titer-glo assay
    		[PMID: 20222733]
    BaF3 GI50
    > 5 μM
    Compound: Erlotinib
    Growth inhibition of mouse BA/F3 cells expressing EGFR Del3 and Thr790Met mutant after 96 hrs by cell titer-glo assay
    Growth inhibition of mouse BA/F3 cells expressing EGFR Del3 and Thr790Met mutant after 96 hrs by cell titer-glo assay
    		[PMID: 20222733]
    BaF3 GI50
    > 5 μM
    Compound: Erlotinib
    Growth inhibition of mouse BA/F3 cells expressing EGFR Del5 and Thr790Met mutant after 96 hrs by cell titer-glo assay
    Growth inhibition of mouse BA/F3 cells expressing EGFR Del5 and Thr790Met mutant after 96 hrs by cell titer-glo assay
    		[PMID: 20222733]
    BaF3 GI50
    > 5 μM
    Compound: Erlotinib
    Growth inhibition of mouse BA/F3 cells expressing EGFR L858R and Thr790Met mutant after 96 hrs by cell titer-glo assay
    Growth inhibition of mouse BA/F3 cells expressing EGFR L858R and Thr790Met mutant after 96 hrs by cell titer-glo assay
    		[PMID: 20222733]
    BaF3 EC50
    16 nM
    Compound: 16
    Cytotoxicity against mouse BaF3 cells expressing EGFR L858R/C797S mutant assessed as reduction in cell viability incubated for 96 hrs by CellTiter-Glo assay
    Cytotoxicity against mouse BaF3 cells expressing EGFR L858R/C797S mutant assessed as reduction in cell viability incubated for 96 hrs by CellTiter-Glo assay
    		[PMID: 37197473]
    BaF3 IC50
    87 nM
    Compound: Erlotinib
    Antiproliferative activity against mouse Ba/F3 cells expressing EGFR-L858R mutant assessed as inhibition of cell growth incubated for 48 hrs by XTT assay
    Antiproliferative activity against mouse Ba/F3 cells expressing EGFR-L858R mutant assessed as inhibition of cell growth incubated for 48 hrs by XTT assay
    		[PMID: 27614407]
    BaF3 IC50
    87 nM
    Compound: Erlotinib
    Inhibition of EGFR L858R mutant (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by XTT assay
    Inhibition of EGFR L858R mutant (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by XTT assay
    		[PMID: 27235841]
    BGC-823 IC50
    11.79 μM
    Compound: 3a; Erlotinib
    Antiproliferative activity against human BGC-823 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human BGC-823 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34416665]
    BT-474 IC50
    > 10 μM
    Compound: Erlotinib
    Antiproliferative activity against human BT474 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human BT474 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 32139324]
    BT-474 IC50
    > 10 μM
    Compound: Tarceva
    Cytotoxicity against human BT474 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human BT474 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 27524310]
    BT-474 IC50
    > 10 μM
    Compound: Erlotinib, Tarceva
    Cytotoxicity against human BT474 cells expressing HER2 after 72 hrs by MTT assay
    Cytotoxicity against human BT474 cells expressing HER2 after 72 hrs by MTT assay
    		[PMID: 24411123]
    BT-474 IC50
    13 μM
    Compound: Erlotinib
    Antiproliferative activity against human BT474 cells after 72 hrs by CellTiter blue assay
    Antiproliferative activity against human BT474 cells after 72 hrs by CellTiter blue assay
    		[PMID: 26599532]
    BT-474 IC50
    6730 nM
    Compound: Erlotinib
    Inhibition of ERBb2 phosphorylation in human BT474 cells by ELISA
    Inhibition of ERBb2 phosphorylation in human BT474 cells by ELISA
    		[PMID: 20817523]
    BXPC-3 EC50
    > 1000 nM
    Compound: Erlotinib
    Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    BXPC-3 IC50
    1.9 μM
    Compound: Erlotinib
    Antiproliferative activity against human BXPC-3 cells measured for 96 hrs by sytox green dye staining based proliferation assay
    Antiproliferative activity against human BXPC-3 cells measured for 96 hrs by sytox green dye staining based proliferation assay
    		[PMID: 27614407]
    BXPC-3 IC50
    7.6 μM
    Compound: erlotinib
    Antiproliferative activity against human BxPC3 cells after hrs by ATP content assay
    Antiproliferative activity against human BxPC3 cells after hrs by ATP content assay
    		[PMID: 20143778]
    C-33-A IC50
    0.9 μM
    Compound: Erlotinib
    Antiproliferative activity against human C-33A cells incubated for 72 hrs by ATPlite luminescence assay
    Antiproliferative activity against human C-33A cells incubated for 72 hrs by ATPlite luminescence assay
    		[PMID: 27614407]
    CAKI-2 EC50
    > 1000 nM
    Compound: Erlotinib
    Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    CAL-27 IC50
    0.074 μM
    Compound: 6
    Cytotoxicity against human CAL27 cells by Alamar Blue assay
    Cytotoxicity against human CAL27 cells by Alamar Blue assay
    		10.1039/C2MD00317A
    CAL-27 IC50
    0.239 μM
    Compound: 3, Tarceva
    Cytotoxicity against human CAL27 cells after 4 days by propidium iodide staining-based fluorometric analysis
    Cytotoxicity against human CAL27 cells after 4 days by propidium iodide staining-based fluorometric analysis
    		[PMID: 22169601]
    Calu-3 IC50
    0.926 μM
    Compound: Erlotinib
    Antiproliferative activity against human Calu3 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human Calu3 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 32139324]
    Calu-3 IC50
    0.93 μM
    Compound: Erlotinib, Tarceva
    Cytotoxicity against human Calu3 cells expressing HER2 after 72 hrs by MTT assay
    Cytotoxicity against human Calu3 cells expressing HER2 after 72 hrs by MTT assay
    		[PMID: 24411123]
    Calu-3 IC50
    4.7 μM
    Compound: Erlotinib
    Antiproliferative activity against human Calu3 cells after 72 hrs by CellTiter blue assay
    Antiproliferative activity against human Calu3 cells after 72 hrs by CellTiter blue assay
    		[PMID: 26599532]
    CAPAN-1 IC50
    > 20 μM
    Compound: erlotinib
    Antiproliferative activity against human Capan1 cells after hrs by ATP content assay
    Antiproliferative activity against human Capan1 cells after hrs by ATP content assay
    		[PMID: 20143778]
    CL97 IC50
    > 20 μM
    Compound: Erlotinib
    Antiproliferative activity against human CL97 cells harbouring EGFR G719A/T790M mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human CL97 cells harbouring EGFR G719A/T790M mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31446247]
    CWR22R IC50
    100 μM
    Compound: 3, Tarceva
    Cytotoxicity against human 22Rv1 cells after 4 days by propidium iodide staining-based fluorometric analysis
    Cytotoxicity against human 22Rv1 cells after 4 days by propidium iodide staining-based fluorometric analysis
    		[PMID: 22169601]
    DU-145 IC50
    0.966 μM
    Compound: 3, Tarceva
    Cytotoxicity against human DU145 cells after 4 days by propidium iodide staining-based fluorometric analysis
    Cytotoxicity against human DU145 cells after 4 days by propidium iodide staining-based fluorometric analysis
    		[PMID: 22169601]
    DU-145 IC50
    18.4 μM
    Compound: 1; Erlo
    Antiproliferative activity against human DU145 cells after 24 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 24 hrs by MTT assay
    		[PMID: 30108891]
    DU-145 IC50
    19.4 μM
    Compound: Erlotinib
    Cytotoxicity against human DU145 cells after 4 to 5 days by MTT assay
    Cytotoxicity against human DU145 cells after 4 to 5 days by MTT assay
    		[PMID: 20466555]
    ECa-109 cell line IC50
    19.22 μM
    Compound: 3a; Erlotinib
    Antiproliferative activity against human EC109 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human EC109 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34416665]
    Erythrocyte IC50
    16.23 μM
    Compound: Erlotinib
    Cytotoxicity against human RBC cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human RBC cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    FaDu IC50
    > 11 μM
    Compound: Erlotinib
    Antiproliferative activity against human FaDU cells assessed as inhibition of cell growth incubated for 72 hrs by Cell Titer Glo luminescent cell viability assay
    Antiproliferative activity against human FaDU cells assessed as inhibition of cell growth incubated for 72 hrs by Cell Titer Glo luminescent cell viability assay
    		[PMID: 27614407]
    GES1 IC50
    17.99 μM
    Compound: 3a; Erlotinib
    Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34416665]
    H9 IC50
    1.3 μM
    Compound: Erlotinib
    Antiproliferative activity against human H9 cells after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against human H9 cells after 72 hrs by CellTiter-Glo assay
    		[PMID: 26599532]
    HCC827 IC50
    0.002 μM
    Compound: Erlotinib
    Cytotoxicity against human HCC827 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCC827 cells after 48 hrs by MTT assay
    		[PMID: 24900830]
    HCC827 IC50
    0.029 μM
    Compound: Erlotinib
    Antiproliferative activity against human HCC827 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCC827 cells after 72 hrs by CCK-8 assay
    		[PMID: 26487917]
    HCC827 IC50
    7.5 μM
    Compound: erlotinib
    Antiproliferative activity against human HCC827 cells after hrs by ATP content assay
    Antiproliferative activity against human HCC827 cells after hrs by ATP content assay
    		[PMID: 20143778]
    HCT-116 IC50
    0.14 μM
    Compound: Tarceva
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 22361272]
    HCT-116 IC50
    1.11 μM
    Compound: Erlotinib
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37122544]
    HCT-116 IC50
    11.21 μM
    Compound: Erlotinib
    Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay
    Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 33065442]
    HCT-116 IC50
    11.57 μM
    Compound: Erlotinib
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    HCT-116 IC50
    13.91 μM
    Compound: Erlotinib
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32361329]
    HCT-116 IC50
    17.86 μM
    Compound: Erlotinib
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35685617]
    HCT-116 IC50
    20.46 μM
    Compound: Erlotinib
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition measured by MTT assay
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition measured by MTT assay
    		[PMID: 34015505]
    HCT-116 IC50
    23.29 μM
    Compound: Erlotinib
    Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay
    		[PMID: 31671308]
    HCT-116 IC50
    65.8 μM
    Compound: 3, Tarceva
    Cytotoxicity against human HCT116 cells after 4 days by propidium iodide staining-based fluorometric analysis
    Cytotoxicity against human HCT116 cells after 4 days by propidium iodide staining-based fluorometric analysis
    		[PMID: 22169601]
    HCT-116 IC50
    7.31 μM
    Compound: Erlotinib
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    		[PMID: 30562699]
    HEK293 IC50
    > 32 μM
    Compound: 6
    Inhibition of human recombinant HDAC1 expressed in human HEK293 cells using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay
    Inhibition of human recombinant HDAC1 expressed in human HEK293 cells using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay
    		10.1039/C2MD00317A
    HEK293 IC50
    > 32 μM
    Compound: 6
    Inhibition of human recombinant HDAC6 expressed in human HEK293 cells using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay
    Inhibition of human recombinant HDAC6 expressed in human HEK293 cells using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay
    		10.1039/C2MD00317A
    HEK293 IC50
    0.55 μM
    Compound: Erlotinib
    Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
    Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
    		[PMID: 22541068]
    HEK293 IC50
    16.2 μM
    Compound: Erlotinib
    Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay
    Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay
    		[PMID: 28230985]
    HEK293 IC50
    21 μM
    Compound: Erlotinib
    Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
    Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
    		[PMID: 22541068]
    HEK293 IC50
    30.3 μM
    Compound: 1; Erlo
    Antiproliferative activity against HEK293 cells after 24 hrs by MTT assay
    Antiproliferative activity against HEK293 cells after 24 hrs by MTT assay
    		[PMID: 30108891]
    HEK293 IC50
    44 μM
    Compound: Erlotinib
    Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
    Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
    		[PMID: 22541068]
    HEK293 IC50
    910 nM
    Compound: Erlotinib
    Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay
    Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay
    		[PMID: 30973735]
    HEK-293T CC50
    104.76 μM
    Compound: Erlotinib
    Cytotoxicity against human HEK293T cells for 24 hrs by MTT assay
    Cytotoxicity against human HEK293T cells for 24 hrs by MTT assay
    		[PMID: 26652482]
    HEK-293T CC50
    28.22 μM
    Compound: Erlotinib
    Cytotoxicity against HEK293T assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HEK293T assessed as reduction in cell viability by MTT assay
    		[PMID: 27234887]
    HEK-293T IC50
    73 μM
    Compound: Erlotinib
    Cytotoxicity against human HEK293T cells after 24 hrs by MTT assay
    Cytotoxicity against human HEK293T cells after 24 hrs by MTT assay
    		[PMID: 30562699]
    HeLa IC50
    > 15.8 μM
    Compound: 6
    Inhibition of HDAC in human HeLa cells using Boc-K(Ac)-AMC as substrate preincubated for 4 hrs before substrate addition measured after 3 hrs by fluorescence assay
    Inhibition of HDAC in human HeLa cells using Boc-K(Ac)-AMC as substrate preincubated for 4 hrs before substrate addition measured after 3 hrs by fluorescence assay
    		10.1039/C2MD00317A
    HeLa IC50
    > 32 μM
    Compound: 6
    Inhibition of HDAC in human HeLa cell nuclear extracts using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay
    Inhibition of HDAC in human HeLa cell nuclear extracts using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay
    		10.1039/C2MD00317A
    HeLa IC50
    0.2 μM
    Compound: Erlotinib
    Antiproliferative activity against human HeLa cells after 12 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 12 hrs by MTT assay
    		[PMID: 26652482]
    HeLa IC50
    14.93 μM
    Compound: Erlotinib
    Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay
    		[PMID: 34995690]
    HeLa IC50
    2.72 μM
    Compound: Erlotinib
    Inhibition of EGFR-TK in human HeLa cells overexpressing EGFR incubated for 18 to 24 hrs by kinase assay
    Inhibition of EGFR-TK in human HeLa cells overexpressing EGFR incubated for 18 to 24 hrs by kinase assay
    		[PMID: 31416740]
    HeLa IC50
    7.48 μM
    Compound: Erlotinib
    Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay
    		[PMID: 31671308]
    HeLa IC50
    8.3 μM
    Compound: 6
    Cytotoxicity against human HeLa cells by Alamar Blue assay
    Cytotoxicity against human HeLa cells by Alamar Blue assay
    		10.1039/C2MD00317A
    Hep 3B2 IC50
    > 20 μM
    Compound: erlotinib
    Antiproliferative activity against human Hep3B2 cells after hrs by ATP content assay
    Antiproliferative activity against human Hep3B2 cells after hrs by ATP content assay
    		[PMID: 20143778]
    HepG2 IC50
    > 20 μM
    Compound: erlotinib
    Antiproliferative activity against human HepG2 cells after hrs by ATP content assay
    Antiproliferative activity against human HepG2 cells after hrs by ATP content assay
    		[PMID: 20143778]
    HepG2 IC50
    0.08 μM
    Compound: Erlotinib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 21816517]
    HepG2 IC50
    0.1 μM
    Compound: Erlotinib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 25172421]
    HepG2 IC50
    0.12 μM
    Compound: Erlotinib
    Antiproliferative activity against human HepG2 cells after 12 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 12 hrs by MTT assay
    		[PMID: 26652482]
    HepG2 IC50
    0.12 μM
    Compound: Erlotinib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 24630412]
    HepG2 IC50
    0.12 μM
    Compound: Erlotinib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 24607998]
    HepG2 IC50
    0.12 μM
    Compound: Erlotinib
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 24144854]
    HepG2 IC50
    0.12 μM
    Compound: Erlotinib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 23962660]
    HepG2 IC50
    0.12 μM
    Compound: ZD 1839
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 23245570]
    HepG2 IC50
    0.12 μM
    Compound: Erlotinib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 22112541]
    HepG2 IC50
    10.17 μM
    Compound: Erlotinib
    Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay
    		[PMID: 34363937]
    HepG2 IC50
    10.23 μM
    Compound: Erlotinib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 33423463]
    HepG2 IC50
    11.57 μM
    Compound: Erlotinib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    HepG2 IC50
    17.68 μM
    Compound: Erlotinib
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured by MTT assay
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured by MTT assay
    		[PMID: 34015505]
    HepG2 IC50
    25 μM
    Compound: Erlotinib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    		[PMID: 31022583]
    HepG2 IC50
    25 μM
    Compound: Erlotinib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 30047410]
    HepG2 IC50
    25 μM
    Compound: Erlotinib
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 24 hrs by spectrophotometry
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 24 hrs by spectrophotometry
    		[PMID: 28487127]
    HepG2 IC50
    25.01 μM
    Compound: Erlotinib
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    		[PMID: 30337229]
    HepG2 IC50
    28.8 μM
    Compound: Erlotinib
    Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
    		[PMID: 31671308]
    HepG2 IC50
    5.8 μM
    Compound: Erlotinib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 26896708]
    HepG2 IC50
    6.73 μM
    Compound: Erlotinib
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32361329]
    HepG2 IC50
    8.19 μM
    Compound: Erlotinib
    Antitumor activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
    Antitumor activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 33065442]
    HepG2 IC50
    9.76 μM
    Compound: 3a; Erlotinib
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34416665]
    HS27 IC50
    > 10000 nM
    Compound: 2
    Cytotoxicity against human HS27 cells after 72 hrs by SRB assay
    Cytotoxicity against human HS27 cells after 72 hrs by SRB assay
    		[PMID: 19888761]
    Hs-578T IC50
    > 100 μM
    Compound: Erlotinib
    Antiproliferative activity against human Hs578T cells after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against human Hs578T cells after 72 hrs by CellTiter-Glo assay
    		[PMID: 26599532]
    HT-29 EC50
    > 1000 nM
    Compound: Erlotinib
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    HT-29 IC50
    > 20 μM
    Compound: Erlotinib
    Anticancer activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Anticancer activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 29549841]
    HT-29 IC50
    0.02 μM
    Compound: ERL
    Cytotoxicity against human HT-29 cells by MTT assay
    Cytotoxicity against human HT-29 cells by MTT assay
    		[PMID: 31129455]
    HT-29 IC50
    0.02 μM
    Compound: Erlotinib
    Antiproliferative activity human HT-29 cells after 48 hrs by propidium iodide staining-based fluorescence assay
    Antiproliferative activity human HT-29 cells after 48 hrs by propidium iodide staining-based fluorescence assay
    		[PMID: 29407956]
    HT-29 IC50
    0.03 μM
    Compound: Erlotinib
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay
    		[PMID: 27010345]
    HT-29 IC50
    0.05 μM
    Compound: 1
    Antiproliferative activity against human HT-29 cells after 48 hrs by propidium iodide fluorescence assay
    Antiproliferative activity against human HT-29 cells after 48 hrs by propidium iodide fluorescence assay
    		[PMID: 30744932]
    HT-29 IC50
    100 μM
    Compound: 3, Tarceva
    Cytotoxicity against human HT-29 cells after 4 days by propidium iodide staining-based fluorometric analysis
    Cytotoxicity against human HT-29 cells after 4 days by propidium iodide staining-based fluorometric analysis
    		[PMID: 22169601]
    HT-29 IC50
    2.98 μM
    Compound: 4
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay
    		[PMID: 25468044]
    HT-29 IC50
    30 nM
    Compound: Erlotinib
    Antiproliferative activity against human HT-29 cells by MTT assay
    Antiproliferative activity against human HT-29 cells by MTT assay
    		[PMID: 37122549]
    HT-29 IC50
    4.37 μM
    Compound: 4
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay
    		[PMID: 25468044]
    HT-29 IC50
    4.63 μM
    Compound: Erlotinib
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33479688]
    Huh-7 CC50
    > 10 μM
    Compound: Erlotinib
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 48 hrs by alamar blue reagent based cell viability assay
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 48 hrs by alamar blue reagent based cell viability assay
    		[PMID: 31757682]
    Huh-7 CC50
    > 20 μM
    Compound: Erlotinib
    Cytotoxicity against DENV-2 New Guinea C infected human Huh-7 cells assessed as reduction in cell viability preincubated for 1 hr followed by viral infection and measured after 48 hrs by Alamar blue assay
    Cytotoxicity against DENV-2 New Guinea C infected human Huh-7 cells assessed as reduction in cell viability preincubated for 1 hr followed by viral infection and measured after 48 hrs by Alamar blue assay
    		[PMID: 33497888]
    Huh-7 EC50
    0.5 μM
    Compound: Erlotinib
    Antiviral activity against Hepatitis C virus J6/JFH infected in human Huh7.5 cells assessed as inhibition of viral replication measured after 72 hrs by luciferase reporter gene assay
    Antiviral activity against Hepatitis C virus J6/JFH infected in human Huh7.5 cells assessed as inhibition of viral replication measured after 72 hrs by luciferase reporter gene assay
    		[PMID: 25822739]
    Huh-7 EC50
    0.5 μM
    Compound: Erlotinib
    Antiviral activity against Hepatitis C virus J6/JFH electroporated in human Huh7.5 cells assessed as inhibition of intracellular infectivity drug treated every 24 hrs for 72 hrs measured 72 hrs post electroporation by luciferase reporter gene assay
    Antiviral activity against Hepatitis C virus J6/JFH electroporated in human Huh7.5 cells assessed as inhibition of intracellular infectivity drug treated every 24 hrs for 72 hrs measured 72 hrs post electroporation by luciferase reporter gene assay
    		[PMID: 25822739]
    Huh-7 EC50
    0.5 μM
    Compound: Erlotinib
    Antiviral activity against Hepatitis C virus J6/JFH infected in human Huh7.5 cells assessed as inhibition of extracellular infectivity drug treated every 24 hrs for 72 hrs measured after 72 hrs by luciferase reporter gene assay
    Antiviral activity against Hepatitis C virus J6/JFH infected in human Huh7.5 cells assessed as inhibition of extracellular infectivity drug treated every 24 hrs for 72 hrs measured after 72 hrs by luciferase reporter gene assay
    		[PMID: 25822739]
    Huh-7 EC50
    1.22 μM
    Compound: Erlotinib
    Antiviral activity against Dengue virus 2 infected in human HuH7 cells incubated for 48 hrs by luciferase reporter gene assay
    Antiviral activity against Dengue virus 2 infected in human HuH7 cells incubated for 48 hrs by luciferase reporter gene assay
    		[PMID: 31757682]
    Huh-7 IC50
    25000 nM
    Compound: Erlotinib
    Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay
    		[PMID: 29057042]
    Jurkat IC50
    12.07 μM
    Compound: Erlotinib
    Antiproliferative activity aganist human Jurkat cells incubated for 72 hrs by MTT assay
    Antiproliferative activity aganist human Jurkat cells incubated for 72 hrs by MTT assay
    		[PMID: 31493743]
    Jurkat IC50
    2 μM
    Compound: erlotinib
    Growth inhibition of human Jurkat cells after 24 hrs
    Growth inhibition of human Jurkat cells after 24 hrs
    		[PMID: 17178722]
    K562 IC50
    55 μM
    Compound: Erlotinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell Titer Glo luminescent cell viability assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell Titer Glo luminescent cell viability assay
    		[PMID: 27614407]
    KB IC50
    0.019 μM
    Compound: Erlotinib
    Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA
    Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA
    		[PMID: 32139324]
    KB IC50
    0.019 μM
    Compound: Erlotinib, Tarceva
    Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA
    Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA
    		[PMID: 24411123]
    KB IC50
    13.01 μM
    Compound: Erlotinib
    Cytotoxicity against human KB cells after 3 days by MTT assay
    Cytotoxicity against human KB cells after 3 days by MTT assay
    		[PMID: 30337229]
    KB IC50
    5 μM
    Compound: 2
    Antiproliferative activity against human KB cells expressing EGFR and Src after 48 hrs by SRB assay
    Antiproliferative activity against human KB cells expressing EGFR and Src after 48 hrs by SRB assay
    		[PMID: 26188620]
    L02 IC50
    18.5 μM
    Compound: Erlotinib
    Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
    Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
    		[PMID: 26896708]
    L02 IC50
    7.25 μM
    Compound: Erlotinib
    Cytotoxicity against human L0-2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human L0-2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 32402937]
    L3.6pl IC50
    4 μM
    Compound: Erlotinib
    Growth inhibition of human L3.6PL cells after 72 hrs by CCK-8 assay
    Growth inhibition of human L3.6PL cells after 72 hrs by CCK-8 assay
    		[PMID: 26547690]
    Leukemia cell IC50
    2 μM
    Compound: erlotinib
    Growth inhibition of JAK2 V617F mutant expressing human erythroleukemia cells after 24 hrs
    Growth inhibition of JAK2 V617F mutant expressing human erythroleukemia cells after 24 hrs
    		[PMID: 17178722]
    Leukemia cell IC50
    2 μM
    Compound: erlotinib
    Growth inhibition of mouse erythroleukemia cells after 24 hrs
    Growth inhibition of mouse erythroleukemia cells after 24 hrs
    		[PMID: 17178722]
    LNCaP IC50
    6.63 μM
    Compound: 3, Tarceva
    Cytotoxicity against human LNCAP cells after 4 days by propidium iodide staining-based fluorometric analysis
    Cytotoxicity against human LNCAP cells after 4 days by propidium iodide staining-based fluorometric analysis
    		[PMID: 22169601]
    LoVo IC50
    0.077 μM
    Compound: 2
    Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay
    Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay
    		[PMID: 23930994]
    LoVo IC50
    8.61 μM
    Compound: Erlotinib
    Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 33423463]
    MCF7 IC50
    > 20 μM
    Compound: Erlotinib
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 29549841]
    MCF7 IC50
    > 20 μM
    Compound: erlotinib
    Antiproliferative activity against human MCF7 cells after hrs by ATP content assay
    Antiproliferative activity against human MCF7 cells after hrs by ATP content assay
    		[PMID: 20143778]
    MCF7 IC50
    > 30 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33479688]
    MCF7 IC50
    > 50 μM
    Compound: 3a; Erlotinib
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34416665]
    MCF7 IC50
    0.01 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 19914837]
    MCF7 IC50
    0.02 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 23245802]
    MCF7 IC50
    0.02 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 22277588]
    MCF7 IC50
    0.02 μM
    Compound: Erlotinib
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 21802290]
    MCF7 IC50
    0.02 μM
    Compound: Erlotinib
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 20627597]
    MCF7 IC50
    0.02 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 20594859]
    MCF7 IC50
    0.02 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 20005116]
    MCF7 IC50
    0.02 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 19914835]
    MCF7 IC50
    0.02 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay
    		[PMID: 27010345]
    MCF7 IC50
    0.03 μM
    Compound: ERL
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 31129455]
    MCF7 IC50
    0.03 μM
    Compound: Erlotinib
    Antiproliferative activity human MCF7 cells after 48 hrs by propidium iodide staining-based fluorescence assay
    Antiproliferative activity human MCF7 cells after 48 hrs by propidium iodide staining-based fluorescence assay
    		[PMID: 29407956]
    MCF7 IC50
    0.07 μM
    Compound: Tarceva
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 22361272]
    MCF7 GI50
    0.08 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 23391364]
    MCF7 IC50
    0.08 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 28988624]
    MCF7 IC50
    0.1 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells after 12 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 12 hrs by MTT assay
    		[PMID: 26652482]
    MCF7 IC50
    0.22 μM
    Compound: Erlotinib
    Antiproliferative activity against Homo sapiens (human) MCF-7 cells overexpressing EGFR assessed as inhibition of cell survival after 48 hr by MTT assay
    Antiproliferative activity against Homo sapiens (human) MCF-7 cells overexpressing EGFR assessed as inhibition of cell survival after 48 hr by MTT assay
    		10.1007/s00044-012-0093-z
    MCF7 IC50
    1.88 μM
    Compound: Erlotinib
    Inhibition of EGFR-TK in human MCF7 cells overexpressing EGFR incubated for 18 to 24 hrs by kinase assay
    Inhibition of EGFR-TK in human MCF7 cells overexpressing EGFR incubated for 18 to 24 hrs by kinase assay
    		[PMID: 31416740]
    MCF7 IC50
    100 μM
    Compound: 3, Tarceva
    Cytotoxicity against human MCF7 cells after 4 days by propidium iodide staining-based fluorometric analysis
    Cytotoxicity against human MCF7 cells after 4 days by propidium iodide staining-based fluorometric analysis
    		[PMID: 22169601]
    MCF7 IC50
    11.18 μM
    Compound: Erlotinib
    Cytotoxicity against human MCF7 cells incubated for 2 to 4 hrs by MTT assay
    Cytotoxicity against human MCF7 cells incubated for 2 to 4 hrs by MTT assay
    		[PMID: 33771586]
    MCF7 IC50
    11.57 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    MCF7 IC50
    11.57 μM
    Compound: Erlotinib
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured by MTT assay
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured by MTT assay
    		[PMID: 34015505]
    MCF7 IC50
    11.7 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
    		[PMID: 31671308]
    MCF7 IC50
    12.4 μM
    Compound: Erlotinib
    Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay
    		[PMID: 34363937]
    MCF7 IC50
    12.42 μM
    Compound: Erlotinib
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 30562699]
    MCF7 IC50
    2.32 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 30503938]
    MCF7 IC50
    2.7 μM
    Compound: Erlotinib
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability in presence of SAHA by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability in presence of SAHA by MTT assay
    		[PMID: 32320239]
    MCF7 EC50
    2.83 μM
    Compound: Erlotinib
    Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay
    		[PMID: 35569690]
    MCF7 IC50
    20 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 30047410]
    MCF7 IC50
    3.11 μM
    Compound: Erlotinib
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32361329]
    MCF7 IC50
    4.03 μg/mL
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells after 24 to 48 hrs by WST1 assay
    Antiproliferative activity against human MCF7 cells after 24 to 48 hrs by WST1 assay
    		[PMID: 22901387]
    MCF7 IC50
    4.1 μM
    Compound: Erlotinib
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition and measured after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition and measured after 72 hrs by SRB assay
    		[PMID: 34000484]
    MCF7 IC50
    4.15 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 3 days by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 3 days by MTT assay
    		[PMID: 32828424]
    MCF7 IC50
    4.16 μM
    Compound: Erlotinib
    Antitumor activity against human MCF7 cells assessed as inhibition of cell viability by MTT assay
    Antitumor activity against human MCF7 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 33065442]
    MCF7 IC50
    40 nM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells by MTT assay
    Antiproliferative activity against human MCF7 cells by MTT assay
    		[PMID: 37122549]
    MCF7 IC50
    8.24 μM
    Compound: Erlotinib
    Antiproliferative activity aganist human MCF7 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity aganist human MCF7 cells incubated for 72 hrs by MTT assay
    		[PMID: 31493743]
    MCF7 IC50
    8.97 μM
    Compound: Erlotinib
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 22985957]
    MDA-MB-231 EC50
    > 1000 nM
    Compound: Erlotinib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    MDA-MB-231 IC50
    > 20 μM
    Compound: erlotinib
    Antiproliferative activity against human MDA-MB-231 cells after hrs by ATP content assay
    Antiproliferative activity against human MDA-MB-231 cells after hrs by ATP content assay
    		[PMID: 20143778]
    MDA-MB-231 IC50
    0.05 μM
    Compound: Erlotinib
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 30562699]
    MDA-MB-231 IC50
    0.48 μM
    Compound: Erlotinib
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
    		[PMID: 32739648]
    MDA-MB-231 IC50
    0.48 μM
    Compound: Erlotinib
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
    		[PMID: 32739648]
    MDA-MB-231 IC50
    14.74 μM
    Compound: 1; Erlo
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 30108891]
    MDA-MB-231 IC50
    15.51 μM
    Compound: Erlotinib
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth by MTT assay
    		[PMID: 32949719]
    MDA-MB-231 IC50
    2.54 μM
    Compound: Erlotinib
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37122544]
    MDA-MB-231 IC50
    30.12 μM
    Compound: Erlotinib
    Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
    		[PMID: 28923383]
    MDA-MB-231 IC50
    33.46 μM
    Compound: Erlotinib
    Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
    		[PMID: 28923383]
    MDA-MB-231 IC50
    34.5 μM
    Compound: 3, Tarceva
    Cytotoxicity against human MDA231 cells after 4 days by propidium iodide staining-based fluorometric analysis
    Cytotoxicity against human MDA231 cells after 4 days by propidium iodide staining-based fluorometric analysis
    		[PMID: 22169601]
    MDA-MB-231 IC50
    4.56 μM
    Compound: Erlotinib
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 32739648]
    MDA-MB-231 IC50
    5.46 μM
    Compound: Erlotinib
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33479688]
    MDA-MB-231 IC50
    55.51 μM
    Compound: Erlotinib
    Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay
    		[PMID: 28923383]
    MDA-MB-231 IC50
    8.3 μM
    Compound: Erlotinib
    Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
    		[PMID: 31671308]
    MEXF276L IC50
    18.6 μM
    Compound: 3, Tarceva
    Cytotoxicity against human MEXF 276L cells after 4 days by propidium iodide staining-based fluorometric analysis
    Cytotoxicity against human MEXF 276L cells after 4 days by propidium iodide staining-based fluorometric analysis
    		[PMID: 22169601]
    MGC-803 IC50
    10.78 μM
    Compound: 3a; Erlotinib
    Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34416665]
    MIA PaCa-2 IC50
    > 10 μM
    Compound: Erlotinib
    Growth inhibition of human MIAPaCa2 cells after 72 hrs by CCK-8 assay
    Growth inhibition of human MIAPaCa2 cells after 72 hrs by CCK-8 assay
    		[PMID: 26547690]
    MIA PaCa-2 IC50
    0.03 μM
    Compound: Erlotinib
    Antiproliferative activity human MIAPaCa2 cells after 48 hrs by propidium iodide staining-based fluorescence assay
    Antiproliferative activity human MIAPaCa2 cells after 48 hrs by propidium iodide staining-based fluorescence assay
    		[PMID: 29407956]
    MIA PaCa-2 IC50
    0.03 μM
    Compound: Erlotinib
    Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay
    Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay
    		[PMID: 27010345]
    MIA PaCa-2 IC50
    0.04 μM
    Compound: ERL
    Cytotoxicity against human MIAPaCa2 cells by MTT assay
    Cytotoxicity against human MIAPaCa2 cells by MTT assay
    		[PMID: 31129455]
    MIA PaCa-2 IC50
    0.04 μM
    Compound: 1
    Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by propidium iodide fluorescence assay
    Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by propidium iodide fluorescence assay
    		[PMID: 30744932]
    MIA PaCa-2 EC50
    27 μM
    Compound: Erlotinib
    Antiproliferative activity against human MIA PaCa-2 cells assessed as cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human MIA PaCa-2 cells assessed as cell viability measured after 72 hrs by MTT assay
    		[PMID: 28105281]
    MIA PaCa-2 IC50
    82.47 μM
    Compound: Erlotinib
    Cytotoxicity against human MIAPaCa2 cells after 4 to 5 days by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 4 to 5 days by MTT assay
    		[PMID: 20466555]
    MKN-45 IC50
    76.7 μM
    Compound: 3, Tarceva
    Cytotoxicity against human MKN45 cells after 4 days by propidium iodide staining-based fluorometric analysis
    Cytotoxicity against human MKN45 cells after 4 days by propidium iodide staining-based fluorometric analysis
    		[PMID: 22169601]
    MRC5 IC50
    5.8 μM
    Compound: Erlotinib
    Antiproliferative activity against human MRC5 cells after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against human MRC5 cells after 72 hrs by CellTiter-Glo assay
    		[PMID: 26599532]
    NCI-H1299 IC50
    28.92 μM
    Compound: Erlotinib
    Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell growth by MTT assay
    Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell growth by MTT assay
    		[PMID: 32949719]
    NCI-H1299 IC50
    3.05 μM
    Compound: Erlotinib
    Antiproliferative activity against human H1299 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human H1299 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33479688]
    NCI-H1299 IC50
    3.33 μM
    Compound: Erlotinib
    Antiproliferative activity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 32739648]
    NCI-H1650 IC50
    > 50 μM
    Compound: 3a; Erlotinib
    Antiproliferative activity against human NCI-H1650 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1650 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34416665]
    NCI-H1975 IC50
    > 1000 nM
    Compound: 2
    Cytotoxicity against human NCI-H1975 cells after 24 hrs by MTT assay
    Cytotoxicity against human NCI-H1975 cells after 24 hrs by MTT assay
    		[PMID: 19888761]
    NCI-H1975 EC50
    > 1000 nM
    Compound: Erlotinib
    Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay
    		[PMID: 27010810]
    NCI-H1975 IC50
    > 20 μM
    Compound: Erlotinib
    Antiproliferative activity against human H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 32402937]
    NCI-H1975 IC50
    10 μM
    Compound: Erlotinib
    Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M double mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M double mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31446247]
    NCI-H1975 IC50
    13.12 μM
    Compound: Erlotinib
    Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33640672]
    NCI-H1975 IC50
    25.63 μM
    Compound: 3a; Erlotinib
    Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34416665]
    NCI-H1975 IC50
    47.6 μM
    Compound: 2
    Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant assessed as inhibition of cell growth by MTT assay
    Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant assessed as inhibition of cell growth by MTT assay
    		[PMID: 31869655]
    NCI-H1975 IC50
    5.51 μM
    Compound: Erlotinib
    Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 32139324]
    NCI-H1975 IC50
    5.51 μM
    Compound: Tarceva
    Cytotoxicity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 27524310]
    NCI-H1975 IC50
    5.51 μM
    Compound: Erlotinib, Tarceva
    Cytotoxicity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay
    		[PMID: 24411123]
    NCI-H1975 IC50
    6.9 μM
    Compound: 2
    Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M mutant after 72 hrs by SRB assay
    Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M mutant after 72 hrs by SRB assay
    		[PMID: 24183742]
    NCI-H1975 IC50
    7.06 μM
    Compound: 2
    Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells assessed as growth inhibition after 72 hrs by SRB assay
    Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 24565969]
    NCI-H1975 IC50
    7.498 μM
    Compound: Erlotinib
    Cytotoxicity against human NCI-H1975 cells after 48 hrs by MTT assay
    Cytotoxicity against human NCI-H1975 cells after 48 hrs by MTT assay
    		[PMID: 24900830]
    NCI-H1975 IC50
    7.6 μM
    Compound: 2
    Inhibition of EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay
    Inhibition of EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay
    		[PMID: 23930994]
    NCI-H1975 IC50
    9000 nM
    Compound: 3
    Inhibition of EGFR L858R/T790M double mutant autophosphorylation in human NCI-H1975 cells after 2 hrs by sandwich ELISA
    Inhibition of EGFR L858R/T790M double mutant autophosphorylation in human NCI-H1975 cells after 2 hrs by sandwich ELISA
    		[PMID: 26756222]
    NCI-H1993 IC50
    2.043 μM
    Compound: Erlotinib
    Cytotoxicity against human NCI-H1993 cells after 48 hrs by MTT assay
    Cytotoxicity against human NCI-H1993 cells after 48 hrs by MTT assay
    		[PMID: 24900830]
    NCI-H23 IC50
    49.3 μM
    Compound: Erlotinib
    Cytotoxicity against human NCI-H23 cells assessed as reduction in cell viability after 46 hrs by MTT assay
    Cytotoxicity against human NCI-H23 cells assessed as reduction in cell viability after 46 hrs by MTT assay
    		[PMID: 29138027]
    NCI-H292 IC50
    1 μM
    Compound: Erlotinib
    Cytotoxicity against human NCI-H292 cells after 72 hrs by SRB assay
    Cytotoxicity against human NCI-H292 cells after 72 hrs by SRB assay
    		[PMID: 25215856]
    NCI-H292 EC50
    31 nM
    Compound: erlotinib
    Antiproliferative activity against human NCI-H292 cells expressing wild type EGFR after 72 hrs by luminescence assay
    Antiproliferative activity against human NCI-H292 cells expressing wild type EGFR after 72 hrs by luminescence assay
    		[PMID: 26455919]
    NCI-H292 IC50
    6.3 nM
    Compound: erlotinib
    Inhibition of EGFR phosphorylation in human NCI-H292 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay
    Inhibition of EGFR phosphorylation in human NCI-H292 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay
    		[PMID: 26455919]
    NCI-H358 IC50
    3.91 μM
    Compound: Erlotinib
    Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability after 48 hrs by cck8 assay
    Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability after 48 hrs by cck8 assay
    		[PMID: 27234887]
    NCI-H358 IC50
    6 μM
    Compound: erlotinib
    Antiproliferative activity against human NCI-H358 cells after hrs by ATP content assay
    Antiproliferative activity against human NCI-H358 cells after hrs by ATP content assay
    		[PMID: 20143778]
    NCI-H358 IC50
    6.85 μM
    Compound: Erlotinib
    Antiproliferative activity against human NCI-H358 cells assessed as viable cells after 48 hrs by CCK8 assay
    Antiproliferative activity against human NCI-H358 cells assessed as viable cells after 48 hrs by CCK8 assay
    		[PMID: 26879314]
    NCI-H460 IC50
    0.02 μM
    Compound: ERL
    Cytotoxicity against human H460 cells by MTT assay
    Cytotoxicity against human H460 cells by MTT assay
    		[PMID: 31129455]
    NCI-H460 IC50
    0.02 μM
    Compound: 1